Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has been assigned an average recommendation of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $20.83.

STOK has been the subject of a number of research analyst reports. Leerink Partners initiated coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an “outperform” rating and a $18.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Wednesday, November 6th. Finally, Leerink Partnrs upgraded Stoke Therapeutics to a “strong-buy” rating in a report on Friday, October 11th.

Stoke Therapeutics Stock Up 1.4 %

Shares of NASDAQ STOK opened at $11.43 on Friday. The business’s 50 day moving average price is $12.73 and its two-hundred day moving average price is $13.79. The company has a market cap of $605.45 million, a PE ratio of -5.44 and a beta of 0.95. Stoke Therapeutics has a twelve month low of $3.77 and a twelve month high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.05. The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $3.46 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. As a group, research analysts anticipate that Stoke Therapeutics will post -2.03 EPS for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $14.05, for a total transaction of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 17.87 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 11.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its holdings in shares of Stoke Therapeutics by 53.2% during the second quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after buying an additional 1,038 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Stoke Therapeutics by 5.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock worth $425,000 after buying an additional 1,642 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after buying an additional 1,994 shares in the last quarter. Quest Partners LLC acquired a new position in shares of Stoke Therapeutics during the second quarter worth $29,000. Finally, Los Angeles Capital Management LLC increased its holdings in shares of Stoke Therapeutics by 7.2% during the second quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock worth $902,000 after buying an additional 4,508 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.